Cramer makes the call on viewers' favorite stocks.   Read More

Patrick Swayze is sadly a statistic. He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year. Several companies are working on drugs for the disease, but the path is littered with failures.    Read More

What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.    Read More